Myriad Illuminates High Court's Approach To Section 101

Law360, New York (July 8, 2013, 12:21 PM EDT) -- On June 13, 2013, the U.S. Supreme Court handed down its long-awaited decision in Association for Molecular Pathology v. Myriad Genetics Inc., in which it found claims to isolated DNA not patent eligible under 35 U.S.C. § 101. The Myriad opinion is interesting not only in its own right, but also for how it illuminates the Supreme Court’s recent approach to cases involving Section 101, an issue with a long and complex history reflecting a variety of legal tests and approaches.

An examination of Myriad together...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.